Optogenetic Therapy Offers Renewed Hope in Retinitis Pigmentosa

Allen C. Ho, MD, FACS, discusses 3-year data from Nanoscope Therapeutics’ MCO-010 program in RP, as well as the potential of this optogenetic approach to treat a broad range of retinal degenerative diseases.

By: Allen C. Ho, MD

Retinal Physician October 19, 2025

Allen C. Ho, MD

Director of Retina Research

Affiliations: Wills Eye Hospital and Mid-Atlantic Retina

Specialties: Ophthalmology

Bio: Allen C. Ho, MD, FACS, is director of retina research at Wills Eye Hospital and Mid-Atlantic Retina. His clinical and research focus includes retinal degenerative diseases and emerging therapeutic approaches for severe vision loss. At the 2025 American Academy of Ophthalmology retina subspecialty day, Dr. Ho presented long-term data from the MCO-010 RESTORE study, an optogenetic therapy program for retinitis pigmentosa. His discussion highlighted mutation-agnostic strategies for retinal degeneration and 3-year follow-up findings in patients with advanced vision loss.

PentaVision

Retinal Physician

Optogenetic Therapy Offers Renewed Hope in Retinitis Pigmentosa

Recommendations